12:00 AM
Jul 02, 2007
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Organoselenium: Phase II started

ALT began a double-blind, placebo-controlled, U.S. Phase II trial (Study 201) in 60 patients with the haptoglobin 2-2...

Read the full 70 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >